

## Cerep enters strategic collaboration with Pfizer based on BioPrint® technology

Rueil-Malmaison, France, January 17, 2003 - press release 2003/01

Cerep announces that it has entered into a multi-year strategic pharmaco-informatics alliance with Pfizer. Through this alliance, Pfizer will have access to BioPrint® data and the derived pharmaco-informatics tools. In addition, Cerep will create exclusive BioPrint® data based on Pfizer proprietary compounds. Pfizer and Cerep will collaborate on the enhancement of BioPrint® and the derived pharmaco-informatics tools. The goal of the collaboration is to develop improved methods for the early prediction of adverse clinical events.

The financial terms of the agreement are not disclosed. Cerep will receive license and development payments for data and pharmaco-informatics tools. First payments correspond to data and tools delivered in 2002.

*"We are particularly happy today to announce this alliance with Pfizer. We recognize Pfizer as having one of the most innovative and forward looking R&D strategies in the pharmaceutical industry. We feel that the two companies, working together, can make significant advances in the development and validation of predictive technologies"* commented Mark Crawford, Executive Vice President for Business Development, Cerep.

*Cerep's mission is to build a pipeline of drug candidates aimed to be licensed out at the beginning of clinical phases. The drug discovery effort is financed through profitable fee for service activities.*

*Cerep provides solutions allowing faster and cost effective drug discovery by identifying at early stages the most promising drug candidates as well as eliminating those compounds likely to fail in development. Cerep's integrated platform encompasses a complete range of technologies including chemistry, biology, and informatics.*

*Cerep's technologies benefit to more than 200 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms.*

*Cerep's drug pipeline includes collaborative drug candidates developed with Bristol-Myers Squibb, Sanofi-Synthélabo and Sepracor, as well as products discovered on its own.*

*Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the company's Document de référence.*

### Contact

Thierry Jean, President and CEO

Tel. +33 (0)1 55 94 84 00

Mark Crawford, executive Vice-President Business Development

Tel. +1 (425) 895 8666

[fincom@cerep.fr](mailto:fincom@cerep.fr)

Code Euroclear France : 6179 – Nouveau Marché